Monday, June 30, 2025 6/30/2025

Redox Regulation of O-GlcNAcylation Signaling in the Pathogenesis of Alcoholic Fatty Liver Disease

Award Number: R01AA028859
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2022
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Redox Regulation of O-GlcNAcylation Signaling in the Pathogenesis of Alcoholic Fatty Liver Disease - PROJECT SUMMARY Alcoholic fatty liver disease (AFLD) is a major cause of chronic liver disease. Globally, AFLD accounts for 0.9% of total mortality and 0.6% of disability-adjusted life years and remains a public health problem worldwide. Despite its profound health and economic impact, the AFLD management remains challenging due to the lack of detailed understanding of determinants of its pathogenesis and progression. The goal of this project is to elucidate a novel role of redox-modulated hepatic O-GlcNAc signaling in alcohol-induced liver injury, and thereby identify potential novel preventive, diagnostic and/or therapeutic targets against AFLD. Oxidative stress is implicated to play a central role in many pathways involved in the initiation and progression of AFLD. Hepatic glutathione (GSH) functions in maintaining cellular redox homeostasis. Intriguingly, chronic GSH deficiency in mice harboring a global disruption of the glutamate-cysteine ligase modifier subunit (Gclm) gene confers protection against alcohol-induced steatosis. Molecular and metabolomics studies indicate that the hepatoprotective effect of low GSH is linked to activations of AMPK signaling pathway and NRF2 antioxidant response, and reprogramming of hepatic metabolism that benefits the maintenance of cellular redox and metabolic homeostasis. Multiomics analyses imply that post-transcriptional mechanisms play a significant role in mediating low GSH-elicited metabolic adaptation upon ethanol exposure. O-GlcNAcylation of protein is a prevalent form of post-translational modification (PTM), where a single O-linked N-acetylglucosamine (O- GlcNAc) moiety is added to nuclear, cytoplasmic and mitochondrial proteins. This process is controlled by a pair of O-GlcNAc cycling enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). In the liver, O- GlcNAc signaling has been shown to serve as an important mechanism for nutrient and stress sensing and subsequent regulation of liver cellular homeostasis. Aberrant O-GlcNAcylation has been implicated in hepatic insulin resistance, fatty liver disease and associated fibrosis. To date, little is known about the role of O- GlcNAcylation in AFLD pathogenesis. Our preliminary studies show that, in GSH-deficient Gclm-null mouse livers, chronic-binge ethanol feeding induced beneficial changes in global O-GlcNAylation and associated cellular pathways and signaling proteins. This project will expand upon these provocative findings and test the hypothesis predicting that adaptive O-GlcNAc signaling driven by chronic oxidative stress (due to GSH deficiency) in the liver protects against alcohol-induced liver injury. We propose to (1) utilize the Gclm-null mouse model to examine ethanol-induced changes in O-GlcNAcylation and phosphorylation modifications of the liver proteome and substrate targeting of O-GlcNAc cycling enzymes, and (2) evaluate the functional impacts of top candidate protein-O-GlcNAcylations in ethanol-associated stress response in human HepaRG cells. The proposed study will be the first examination of in vivo interplay between hepatic redox status and O- GlcNAcylation signaling in the context of alcohol induced liver injury.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $376,875 )
2025	2025	YALE UNIV	150 MUNSON ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Alcohol Research Programs	000	4	4/23/2025	NON-COMPETING CONTINUATION	$376,875
														Subtotal = $376,875

Issue Date FY: 2024 ( Subtotal = $376,875 )
2024	2024	YALE UNIVERSITY	105 WALL ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Alcohol Research Programs	000	3	2/7/2024	NON-COMPETING CONTINUATION	$339,188
2024	2024	YALE UNIV	150 MUNSON ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Alcohol Research Programs	001	3	5/17/2024	NON-COMPETING CONTINUATION	$37,687
														Subtotal = $376,875

Issue Date FY: 2023 ( Subtotal = $376,875 )
2023	2023	YALE UNIVERSITY	105 WALL ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Alcohol Research Programs	000	2	2/14/2023	NON-COMPETING CONTINUATION	$376,875
														Subtotal = $376,875

Issue Date FY: 2022 ( Subtotal = $376,875 )
2022	2022	YALE UNIVERSITY	105 WALL ST	NEW HAVEN	CT	06511	SOUTH CENTRAL CT	USA	Alcohol Research Programs	000	1	4/25/2022	NEW	$376,875
														Subtotal = $376,875

Grand Total All Awards = $1,507,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Redox Regulation of O-GlcNAcylation Signaling in the Pathogenesis of Alcoholic Fatty Liver Disease

Award Number: R01AA028859

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2022

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer